CNS-Penetrant LPA₁ Antagonist PIPE-791 Provides Superior Analgesia Compared to Peripherally-Restricted CTX-343 in a Rat Model of LPA-Induced Osteoarthritis

/in , /by

A. R. Broadhead, C. S. Baccei, D. Bagnol, K. I. Lorrain, G. C. Edu, M. M. Poon, J. R. Roppe, T. O. Schrader, L. J. Valdez, Y. Xiong, A. C. Chen, D. S. Lorrain

Presented at SFN 2025

LPA1 receptor binding sites are abundant in multiple sclerosis patient rim lesions associated with TSPO activation and disease progression

/in , /by

D. Bagnol, A. R. Broadhead, C. S. Baccei, K. I. Lorrain, G. C. Edu, K. Stebbins, M. M.
Poon, J. R. Roppe, T. O. Schrader, L. J. Valdez, A. C. Chen, D. S. Lorrain

Presented at SFN 2025

LPA-Induced Activation of Satellite Glial Cells and Its Modulation by PIPE-791, a novel LPA1 antagonist, in an In Vitro Pain Model

/in , /by

K.I. Lorrain, A. R. Broadhead, D. Bagnol, M. M. Poon, G. Joseph, J.R. Roppe, A. C. Chen, D. S. Lorrain

Presented at SFN 2025

Exploring the Effects of SARM1 Inhibition in Preventing Neurodegeneration in Human and Rodent Neuropathic Pain Models

/in , /by

Cameron Pernia, Geraldine Edu, Kymmy Lorrain, Greg Joseph, Didier Bagnol, Thomas Schrader, Michael Poon, Daniel Lorrain

Presented at American College of Neuropsychopharmacology 2025

Active MS lesions are characterized by high LPA1 expression and PIPE-791 promotes remyelination via LPA1 inhibition in the cuprizone model

/in , /by

Didier Bagnol, Alexander R Broadhead, Geraldine C Edu, John Atkins, Christopher S Baccei, Kym I Lorrain, Michael M Poon, Jeffrey R Roppe, Thomas O Schrader, Lino J Valdez, Yifeng Xiong, Austin C Chen, Daniel S Lorrain

Presented at Gordon Research Conference (GRC) 2024

PIPE-791 inhibits LPA1 to promote myelination and limit neuroinflammation

/in , /by

Michael M Poon, Kym I Lorrain, Geraldine Edu, Karin J Stebbins, Alexander Broadhead, Ariana J Lorenzana, Jeffrey R Roppe, Austin C Chen, Daniel S Lorrain

Presented at Gordon Research Conference (GRC) 2023

Small molecule inhibition of the muscarinic M1 acetylcholine receptor by potent, selective antagonists facilitate OPC differentiation

/in , /by

Michael M Poon, Kym I Lorrain, Ariana O Lorenzana, Karin J Stebbins, Alexander Broadhead, Thomas O Schrader, Yifeng Xiong, Jill Baccei, Ari J

Presented at Neuroscience 2019

PIPE-359, a novel, potent and selective M1 muscarinic receptor antagonist as a therapeutic approach for remyelination in multiple sclerosis

/in , /by

Karin J Stebbins, Michael M Poon, Alexander Broadhead, Geraldine Edu, Ariana Lorenzana, Kym I Lorrain, Thomas Schrader, Yifeng Xiong, Jill Baccei, Christopher Baccei, Ari J Green

Presented at Neuroscience 2019

Discovery of PIPE-359, a Brain-Penetrant, Selective M1 Receptor Antagonist with Robust Efficacy in Murine MOG-EAE

/in , /by

Thomas O. Schrader, Yifeng Xiong, Ariana O. Lorenzana, Alexander Broadhead, Karin J. Stebbins, Michael M. Poon, Christopher Baccei, and Daniel S. Lorrain

ACS Medicinal Chemistry Letters

Discovery of a Novel M1 Selective Antagonist, PIPE-307, for the Treatment of Multiple Sclerosis

/in , /by

Kym I Lorrain, Michael M Poon, Alexander Broadhead, Karin J Stebbins, Austin Chen, Jill Baccei, Ari J Green, Jonah R Chan, Daniel S Lorrain

Presented at Neuroscience 2021

©2026 Contineum Therapeutics Terms of Use Privacy Policy Linkedin Linkedin